Jiyoung Kim, Ph.D. is a staff scientist working in the U.R.S.INI lab since March 2021. Her research interest is to identify the mechanisms through which genomic risk for schizophrenia (SCZ) interacts with early life events, like prenatal and perinatal complications associated with placenta’s pathophysiology. She is currently working on modeling human trophoblast from patients and control groups, to characterize whether genomic risk for SCZ patients corresponds to phenotypic differences in differentiated trophoblast, syncytiotrophoblast, and extravillous trophoblasts.
She earned her BS, MS, and Ph.D. from Seoul, Korea, where she studied germline development in small animal model system intensively being trained on forward and reverse genetics. Before joining the Lieber Institute, she was a postdoctoral fellow at the National Institutes of Health, in Baltimore, where her research was focused on post-transcriptional gene regulation by long noncoding RNAs in human cancer. She has also worked at Elixirgen Scientific, LLC and Elixirgen Therapeutics, Inc., as a scientist to develop comprehensive kits for differentiation of various types of neuron and brain organoids using human iPSCs, and participate in pre-IND drug development for age-related diseases as well as a COVID-19 vaccine.